Acute Ischemic Stroke: Global Market Value to Grow Significantly by 2017, but Clinical Trial Challenges Remain
The acute ischemic stroke (AIS) therapeutics market in the six major countries — the US, France, Germany, Italy, Spain and UK — is forecast to jump from $531 million in 2012 to $1.2 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 17.3%, says a new report from research and consulting firm GlobalData.
According to the company’s latest report*, the US market will continue to generate the majority of sales, more than doubling its revenue from $376.4 million in 2012 to $945.4 million by 2017, at a CAGR of 20.2%. This is due to the US having the highest prevalence and incidence of AIS and comparatively high AIS therapy prices.
Paul Sue, Analyst for GlobalData, says: “A major driver of the AIS market is the launch of desmoteplase, a novel next-generation thrombolytic, which has an extended therapeutic time window when compared with the current standard of care, Activase/Actilyse. In addition, the increasing prominence of telemedicine, whereby patients get medical information over the phone or on the internet, will enhance accessibility to vital stroke care and treatment.”
However, there are many barriers associated with AIS clinical trials that need to be overcome for new therapies to be developed successfully.
Sue says: “A fundamental challenge with both reperfusion and neuroprotective trials design is stroke heterogeneity. Most late-stage clinical trials conducted in the US and Europe to date, including all Phase III trials of neuroprotective agents for AIS, have been negative due to unrealistic study endpoints. In fact, there is currently limited agreement on what constitutes a minimally important treatment effect in AIS trials.
“Other common issues in such trials, which will require more robust consideration for future studies, include testing drugs too long after stroke onset, and poor patient selection for these trials,” the analyst concludes.
*OpportunityAnalyzer: Acute Ischemic Stroke — Opportunity Analysis and Forecasts to 2017
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance